Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS

S. Gheuens, D. R. Smith, X. Wang, D. C. Alsop, R. E. Lenkinski, I. J. Koralnik*

*Corresponding author for this work

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Objective: Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab therapy in patients with multiple sclerosis (MS), which is often accompanied by an immune reconstitution inflammatory syndrome (IRIS) after removal of the drug. We describe a patient with MS who presented with simultaneous PML-IRIS 2 months after stopping natalizumab for other reasons. Case Report and Results: The patient had widespread PML and severe IRIS. He received corticosteroids and displayed a vigorous JC virus-specific cellular immune response. Elevated myoinositol and lipid/creatine peaks measured in PML lesions by proton magnetic resonance spectroscopy (1H-MRS) corresponded to episodes of contrast enhancement on MRI scans and persisted after the enhancement subsided. He demonstrated steady clinical improvement, but developed marked residual atrophy in areas affected by PML and inflammation, as well as seizures. Conclusions: New enhancing white matter lesions, occurring after discontinuation of natalizumab, can be the manifestation of PML-IRIS rather than an MS exacerbation. Elevated myoinositol and lipid/creatine peaks appear to be more sensitive markers of inflammation in PML lesions than contrast enhancement. 1H-MRS may become useful as a biomarker for PML-IRIS by helping clinicians determine the need for corticosteroid administration and anticipate continuing clinical recovery.

Original languageEnglish (US)
Pages (from-to)1390-1393
Number of pages4
JournalNeurology
Volume78
Issue number18
DOIs
StatePublished - May 1 2012

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS'. Together they form a unique fingerprint.

  • Cite this